Lieberman Gerald M reported grant involving 7,242 derivative units of TEVA PHARMACEUTICAL INDUSTRIES LTD at $0.00 for $0 on May 28, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 1, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
7,242Restricted Share Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
7,242Direct
Trade date
May 28, 2026Grant
Filed
Jun 1, 2026, 4:11 PM ET4-day reporting delay
Accession
0001193125-26-251434Code A · Transaction 388147
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −13%1w ago +0.9%1d ago +0.9%
Returns since7d 0%30d −3.5%90d +5.2%180d1y

Footnotes in full

F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.